Neural drug delivery system with fluidic threads

• US 9,155,861 B2
• Filed: 09/20/2011
• Issued: 10/13/2015
• Est. Priority Date: 09/20/2010
• Status: Active Grant

• Current Assignee: Neuronexus Technologies Incorporated (NEL Group, Inc.)
• Original Assignee: Neuronexus Technologies Incorporated (NEL Group, Inc.)
• Inventors: Hetke, Jamille F., Kipke, Daryl R., Vetter, Rio J.
• Primary Examiner(s): HAYMAN, IMANI N
• Application Number:
  US13/236,973
• Publication Number:
  US 20120078188A1
• Time in Patent Office: 1,484 Days
• Field of Search: 604/20, 604/21, 604/66, 604/173, 604/890.1, 604/891.1
• US Class Current: 1/1
• CPC Class Codes: A61M 2025/0058 having an electroactive polymer material, e.g. for steering purposes, for control of flexibility, for locking, for opening or closing
• CPC Class Codes: A61M 2210/1003 Spinal column
• CPC Class Codes: A61M 25/007 Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked

Abstract

A neural drug delivery system with fluidic threads implantable into tissue, including: a plurality of fluid delivery conduits configured to transport fluid and having an array of fluid delivery ports through which the fluid is selectively released; a plurality of port gates each including a mesh structure coupled to a corresponding fluid delivery port and coated with an electroactive polymer; a voltage source providing a conductive signal; and an interconnect network that carries the conductive signal to the port gates. In response of the electroactive polymer to the conductive signal, each port gate is selectively operable between a closed mode that prevents transfer of fluid through its corresponding fluid delivery port to the tissue, and an open mode that allows transfer of the fluid through its corresponding fluid delivery port to the tissue.

Claims

1. A neural drug delivery system, which comprises:

a) at least one fluid delivery conduit comprising a conduit sidewall defining a lumen configured to transport fluid;

b) at least two fluid delivery ports extending through the conduit sidewall;

c) a respective port gate supported by the conduit sidewall at each of the at least two fluid delivery ports, each port gate comprising;

i) a thin-film mesh structure; and

ii) an electroactive polymer supported by at least a portion of the mesh structure,

d) wherein each port gate is selectively operable between the following modes;

i) in the absence of a conductive signal applied to the electroactive polymer, the polymer is stable in an oxidized and expanded state occluding the mesh structure to thereby provide the port gate in a closed mode that prevents transfer of the fluid through the corresponding fluid delivery port; and

ii) in response to a conductive signal applied to the electroactive polymer, the polymer volumetrically contracts to thereby provide an open mode that allows transfer of the fluid through the fluid delivery port;

e) a voltage source that provides the conductive signal to the electroactive polymer of the port gates; and

f) an interconnect network configured to carry the conductive signal to the port gates from the voltage source.

2. The neural drug delivery system of claim 1 wherein the fluid delivery conduit comprises a tube with multiple lumens.

3. The neural drug delivery system of claim 1, further comprising a stylet insertable into the lumen.

4. The neural drug delivery system of claim 1, wherein the at least two fluid delivery ports are arranged at least one of axially along and circumferentially around. the fluid delivery conduit.

5. The neural drug delivery system of claim 1, wherein the port gates supported. by the conduit sidewall at each of the fluid delivery ports further operate in one or more gradient open modes, wherein in each gradient open mode the port gate volumetrically contracts by a discrete amount corresponding to one of a range of conductive signal levels.

6. The neural drug delivery system of claim 1, wherein the electroactive polymer coating is an anion transporting variant of polypyrrole (PPy).

7. The neural drug delivery system of claim 6, wherein the anion transporting variant of polypyrrole (PPy) is characterized as being the product of electropolymerizing polypyrrole in the presence of anions selected from the group consisting of ClO₄, Bf₄, and PF₆.

8. The neural drug delivery system of claim 6, wherein the anion transport variant of polypyttole (PPy) is selected from the group consisting of PPy(C1) gels, PPy(C10₄) gels reaching approximately 43% strain, PPy(CF₃SO₃) gels reaching approximately 19% strain, and PPy(PF₆)reaching approximately 15% strain.

9. The neural drug delivery system of claim 1, wherein the interconnect network includes a central spine arranged along the at least one fluid delivery conduit and one or more branches extending outwardly from the central spine, wherein each branch extends from the central spine to a respective port gate.

10. The neural drug delivery system of claim 9, wherein the central spine of the interconnect network extends axially along the fluid delivery conduit.

11. The neural drug delivery system of claim. 1, further comprising an electrode array that includes an electrode site proximate to one of the at least two fluid delivery ports.

12. The neural drug delivery system of claim 11, wherein the electrode array includes an annular electrode site positioned around a perimeter of at least one of the fluid delivery ports.

13. The neural drug delivery system of claim 11, wherein the electrode array comprises at least one stimulation electrode site.

14. The neural drug delivery system of claim 1, wherein port gates exhibit leakage less than 1 nanoliter/minute in the closed mode.

15. The neural drug delivery system of claim 1, wherein the port gates allow fluid flow of approximately 0.5 to 10 microliters/minute in the open mode.

16. The neural drug delivery system of claim 1, wherein the port gates comprising the electroactive polymer remain stable at 37′

C.

17. A neural drug delivery device, which comprises

a) at least one fluid delivery conduit comprising a conduit sidewall defining a lumen configured to transport fluid;

b) at least one fluid delivery port extending through the conduit sidewall; and

c) a port gate supported by the conduit sidewall at the fluid delivery port, the port gate comprising;

i) a mesh structure; and

ii) an electroactive polymer supported by at least a portion of the mesh structure,

d) wherein the port gate is selectively operable between the following modes;

i) in the absence of a conductive signal applied to the electroactive polymer, the polymer is stable in an oxidized and expanded state occluding the mesh structure to thereby provide the port gate in a closed mode that prevents transfer of the fluid through the fluid delivery port; and

ii) in response to a conductive signal applied to the electroactive polymer, the polymer volumetrically contracts to thereby provide an open mode that allows transfer of the fluid through the fluid delivery port.

18. The neural drug delivery device of claim 17, further including an electrode array including at least one annular stimulation or recording electrode site positioned around a perimeter of the at least one fluid delivery port.

19. The neural drug delivery device of claim 17, wherein the electroactive polymer coating is an anion transporting variant of polypyrrole (PPy).

20. The neural drug delivery device of claim 17, wherein there are at least two fluid delivery ports extending through the conduit sidewall with respective port gates supported by the fluid delivery conduit and wherein a first one of the port gates is operable between the closed and open modes independently of a second port gate.

21. The neural drug delivery device of claim 17, wherein there are at least two fluid delivery conduits with at least one fluid delivery port extending through the respective conduit sidewalls, the delivery ports supporting respective port gates and wherein a first one of the port gates is operable between the closed and open modes independently of a second port gate.

22. The neural drug delivery device of claim 17, wherein the port gate supported by the conduit sidewall at the fluid delivery port further operate in one or more gradient open modes, wherein in each gradient open mode the port gate volumetrically contracts by a discrete amount corresponding to one of a range of conductive signal levels.

23. A neural drug delivery system, which comprises:

a) at least one fluid delivery conduit comprising a conduit sidewall defining a. lumen configured to transport fluid;

b) at least one fluid delivery port extending through the conduit sidewall;

c) a port gate supported by the conduit sidewall at the fluid delivery port, the port gate comprising;

i) a thin-film mesh structure; and

ii) an electroactive polymer supported by at least a portion of the mesh structure,

d) wherein the port gate is selectively operable between the following modes;

i) in the absence of a conductive signal applied to the electroactive polymer, the polymer is stable in an oxidized and expanded state occluding the mesh structure to thereby provide the port gate in a closed. mode that prevents transfer of the fluid through the fluid delivery port;

ii) in response to a conductive signal being applied to the electroactive polymer, the polymer volumetrically contracts to thereby provide an open mode that allows transfer of the fluid through the fluid delivery port; and

iii) one or more gradient open modes, wherein in each gradient open mode the port gate volumetrically contracts by a discrete amount corresponding to one of a range of conductive signal levels; and

e) a voltage source that provides the conductive signal to the electroactive polymer of the port gate; and

f) an interconnect network configured to carry the conductive signal to the port gate from the voltage source.

24. The neural drug delivery system of claim 23, wherein the electroactive polymer coating is an anion transporting variant of polypyrrole (PPy).

25. The neural drug delivery system of claim 23, wherein the port gates exhibit leakage less than 1 nanoliter/minute in the closed mode.

26. The neural drug delivery system of claim 23, wherein the port gates allow fluid flow or approximately 0.5 to 10 microliters/minute in the open mode.

27. The neural drug delivery system of claim 23, wherein the port gates comprising the electroactive polymer remain stable at 37°

C.